EUVIMEDOpdag EUVIMED
Crossref

Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7

Gina M Connors, Thao D Pham, Jeffrey H Becker, Aria A Argus, Kenkichi Baba, Takayoshi Kinoshita, Hidayatullah G Munshi, Karl A Scheidt iD

ACS Chemical Biology · 2026

DOI: 10.1021/acschembio.6c00580 ↗

At a glance

Journal article in ACS Chemical Biology, 2026. Written by Gina M Connors and 7 co-authors. Institution: Department of Chemistry, Northwestern University, Evanston, Illinois60208, United States. Major MEDLINE topics: Drug Resistance, Neoplasm, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, MAP Kinase Kinase 4. 47 references. Funded by: NCI NIH HHS, Osaka University, Northwestern University.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Pancreatic ductal adenocarcinoma (PDAC) is highly lethal and remains largely refractory to targeted therapy despite its near-universal dependence on oncogenic KRAS. Single-agent KRAS inhibitors often fail due to adaptive resistance mechanisms that emerge under pharmacologic pressure. Previous studies combining MAP2K4 inhibition with KRASG12C-targeted therapy determined that partial JNK suppression can enhance anticancer responses. Here, we extend this concept to PDAC, which is predominantly driven by KRASG12D mutations, and demonstrate that full JNK pathway inactivation restores sensitivity to KRAS inhibition in resistant cells. Using selective MAP2K4, MAP2K7, or combined inhibitors, we show that more extensive JNK suppression disables the feedback loop that reactivates KRAS signaling. In contrast, KRASG12D inhibitor-sensitive cells derive no benefit from JNK pathway inhibition, revealing a resistance-specific vulnerability amenable to therapeutic exploitation.

Subjects

MeSH terms (MEDLINE)

Drug Resistance, NeoplasmPancreatic NeoplasmsCarcinoma, Pancreatic DuctalMAP Kinase Kinase 4Protein Kinase InhibitorsAntineoplastic AgentsHumansProto-Oncogene Proteins p21(ras)Cell Line, Tumor

Substances

MAP Kinase Kinase 4Proto-Oncogene Proteins p21(ras)Protein Kinase InhibitorsMAP2K4 protein, humanAntineoplastic AgentsKRAS protein, human

Authors and institutions

  • Department of Chemistry, Northwestern University, Evanston, Illinois60208, United States.
  • Department of Medicine, Feinberg School of Medicine, and The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois60611, United States.
  • Graduate School of Science, Osaka Metropolitan University, Sakai, Osaka599-8531, Japan.

ORCID profiles: Karl A Scheidt

Funding

  • NCI NIH HHS
  • Osaka University
  • Northwestern University
  • National Cancer Institute

Cite

APA

Connors, G. M., Pham, T. D., Becker, J. H., Argus, A. A., Baba, K., Kinoshita, T., Munshi, H. G., & Scheidt, K. A. (2026). Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00580

Vancouver

Connors GM, Pham TD, Becker JH, Argus AA, Baba K, Kinoshita T, et al. Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00580

BibTeX
@article{Connors2026,
  author = {Connors, Gina M and Pham, Thao D and Becker, Jeffrey H and Argus, Aria A and Baba, Kenkichi and Kinoshita, Takayoshi and Munshi, Hidayatullah G and Scheidt, Karl A},
  title = {Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7},
  journal = {ACS Chemical Biology},
  year = {2026},
  doi = {10.1021/acschembio.6c00580}
}
Start for free →